‘Unlist us’ Amarantus asks Berlin-Bremen stock exchange
This article was originally published in Scrip
Sunnyvale, California-based Amarantus BioSciences, a biotech company developing treatments and diagnostics for Parkinson's disease and traumatic brain injury, has initiated legal action to get itself removed from the Berlin-Bremen Stock Exchange (BBSE), on which it is being traded without consent.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.